Citations Shor, R., et al, "Glucagon-Like Peptide-1 Receptor Agonists and Risk of Neovascular Age-Related Macular Degeneration," JAMA Ophthalmology, June 5, 2025, doi: 10.1001/jamaophthalmol.2025.1455 Edinoff, A.N., et al, "Selective Serotonin Reuptake Inhibitors and Associated Bleeding Risks: A Narrative and Clinical Review," Health Psychology Research, Nov 3, 2022, DOI: 10.52965/001c.39580 Dalton, S.O., et al, "SSRIs and upper gastrointestinal bleeding: what is known and how should it influence prescribing?," CNS Drugs, 2006, DOI: 10.2165/00023210-200620020-00005 Hussain, S., et al, "Proton pump inhibitors' use and risk of hip fracture: a systematic review and meta-analysis," Rheumatology International, Nov
NIDA Res
effects on fat metabolism in humans are still being characterised and should not be overstated Glucagon receptor increases energy expenditure and promotes fat breakdown, though it may also raise hepatic glucose output
This stability eliminates the need for protective carriers that other therapeutic peptides require
Some patients develop gallbladder problems, including gallstones or even gallbladder inflammation (cholecystitis), during treatment